Figures & data
Table I. Protocol of aerobic physical activity and Mediterranean diet's principles observed by patients during the study.
Figure 1. Representative flow cytometric scattergrams showing the gating strategy used. Upper panels, after PhA standard aerobic protocol in patients with ED; lower panels, before PhA aerobic protocol. Both histograms 1 report the forward versus side scatter dot plot: three different cell populations can be identified (gate F: lymphocytes; gate I: monocytes; gate J: polymorphonuclear cells). Both histograms 2 report the CD45pos (E) and CD45neg (G) cells. Both histograms 3 report only the CD45neg cells (gate G) subdivided according to the expression of CD34 and CD144 antigen staining. EPCs were defined as CD45neg/CD34pos/CD144pos, whereas EMP CD45neg/CD34neg/CD144pos.
![Figure 1. Representative flow cytometric scattergrams showing the gating strategy used. Upper panels, after PhA standard aerobic protocol in patients with ED; lower panels, before PhA aerobic protocol. Both histograms 1 report the forward versus side scatter dot plot: three different cell populations can be identified (gate F: lymphocytes; gate I: monocytes; gate J: polymorphonuclear cells). Both histograms 2 report the CD45pos (E) and CD45neg (G) cells. Both histograms 3 report only the CD45neg cells (gate G) subdivided according to the expression of CD34 and CD144 antigen staining. EPCs were defined as CD45neg/CD34pos/CD144pos, whereas EMP CD45neg/CD34neg/CD144pos.](/cms/asset/28c43658-52fe-4d36-9bc0-80e2784b4a28/itam_a_544344_f0001_b.gif)
Table II. Penile dynamic echo-color doppler parameters, IIEF-5 score and metabolic features (mean ± SEM) of the patients (group A and group B) with arterial erectile dysfunction at baseline and after three months of standard aerobic protocol of physical activity.
Figure 2. Percentage of circulating endothelial progenitor cells (immunophenotype CD45neg/CD34pos/CD144pos) and percentage of circulating endothelial microparticles (immunophenotype CD45neg/CD34neg/CD144pos) in all patients with ED at baseline (group A compared to group B).
![Figure 2. Percentage of circulating endothelial progenitor cells (immunophenotype CD45neg/CD34pos/CD144pos) and percentage of circulating endothelial microparticles (immunophenotype CD45neg/CD34neg/CD144pos) in all patients with ED at baseline (group A compared to group B).](/cms/asset/6ecbb6b1-eee3-4fd8-9adf-16b3eb47a154/itam_a_544344_f0002_b.gif)
Figure 3. Percentage of circulating endothelial progenitor cells (immunophenotype CD45neg/CD34pos/CD144pos) and percentage of circulating endothelial microparticles (immunophenotype CD45neg/CD34neg/CD144pos) in all patients with ED after 3 months of PhA standard aerobic protocol (group A compared to group B).
![Figure 3. Percentage of circulating endothelial progenitor cells (immunophenotype CD45neg/CD34pos/CD144pos) and percentage of circulating endothelial microparticles (immunophenotype CD45neg/CD34neg/CD144pos) in all patients with ED after 3 months of PhA standard aerobic protocol (group A compared to group B).](/cms/asset/62a5b28f-4362-4d82-9697-25134cbfe2e8/itam_a_544344_f0003_b.gif)